Company with closely related technology to Prima Biomed on the up with a target of US$10
"Dendreon Corp. (DNDN, $6.17, +$1.07, +20.98%) has been one of the worst-performing biotech stocks over the last two years amid reimbursement issues for its Provenge prostate cancer drug, but Bernstein said Friday that interviews with the drug's "busiest prescribers" showed they are not only increasing their use but recruiting others to use the product as well. With that, Bernstein forecasted "slow but steady revenue growth" for Dendreon and said it sees signs the "progressive disaster" at the company could be coming to an end. The firm raised its price target by 43% to $10 a share and upgraded the stock to an outperform rating."
http://online.wsj.com/article/BT-CO-20130111-711632.html
Company with closely related technology to Prima Biomed on the...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.8¢ |
Change
-0.003(0.63%) |
Mkt cap ! $566.2M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.5¢ | $395.6K | 994.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 71937 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 187162 | 12 |
View Market Depth
| Last trade - 14.34pm 20/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |